Trials / Terminated
TerminatedNCT03807856
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute pancreatitis.
Detailed description
Subjects with acute pancreatitis who meet the inclusion and exclusion criteria for the study will be recruited. Subjects will be randomized to receive either Dabigatran 150mg daily for three days or standard treatment. Vital signs, CBC, inflammatory markers and BMP, and bleeding complications will be evaluated daily for the next 7 days of until discharge whichever is sooner.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dabigatran Etexilate Mesylate | Dabigatran 150mg BID for 3 days |
| OTHER | Standard of Care | Daily vital signs, lab work and one outpatient clinic visit |
Timeline
- Start date
- 2019-06-24
- Primary completion
- 2020-07-23
- Completion
- 2020-07-23
- First posted
- 2019-01-17
- Last updated
- 2022-09-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03807856. Inclusion in this directory is not an endorsement.